Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight decline in stock price while maintaining a stable financing balance and positive revenue growth [1][2]. - As of February 6, Weigao Blood Purification's stock price decreased by 0.69%, with a trading volume of 33.35 million yuan. The net financing purchase on that day was 1.54 million yuan, with a total financing and securities balance of 123 million yuan [1]. - The company reported a revenue of 2.736 billion yuan for the period from January to September 2025, reflecting a year-on-year growth of 3.45%, and a net profit attributable to shareholders of 341 million yuan, which is a 7.92% increase year-on-year [2]. Group 2 - The company has a significant portion of its revenue coming from consumables, accounting for 77.55%, while equipment contributes 18.25%, and other sources make up 2.35% and 1.85% respectively [1]. - As of September 30, the number of shareholders for Weigao Blood Purification was 24,800, a decrease of 20.95% from the previous period, while the average circulating shares per person increased by 26.51% to 1,535 shares [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].
威高血净2月6日获融资买入399.25万元，融资余额1.22亿元